Correction: Biomark Res 11, 33 (2023)
https://doi.org/10.1186/s40364-023-00473-w
The authors found that an identical image (HUCCT1-Combine) was unintentionally overlaid in another region (HUCCT1-shHMGA1-1) of Fig. 6C, as a result of a malfunction in the AI import system (Adobe Illustrator CS5).
PF-04691502 works synergistically with palbociclib to inhibit iCCA growth, EMT and stemness in vitro. CCK − 8 assay (A), colony formation assay (B), 3D sphere formation assay (C), and transwell assay (D) analysis of iCCA cells treated with a single agent (PF-04691502 or palbociclib), a combination of both compounds at a fixed ratio (1:1) or shRNA-induced silencing of HMGA1. Analyzed data were from three independent experiments and shown as means ± SEM. Analysis for statistical significance was performed using Student’s t-test (n.s.,**, *** and **** represented not significant, P < 0.01, < 0.001and < 0.0001, respectively)
The authors wish to make the necessary replacement for the image in Fig. 6C (HUCCT1-shHMGA1-1) shown in this correction article [1].
All co-authors agree to the above revision.
Reference
Li Z, et al. HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma. Biomark Res. 2023;11:33. https://doi.org/10.1186/s40364-023-00473-w.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Li, Z., Zhou, H., Xia, Z. et al. Correction: HMGA1 augments palbociclib efficacy via PI3K/mTOR signaling in intrahepatic cholangiocarcinoma. Biomark Res 12, 27 (2024). https://doi.org/10.1186/s40364-024-00574-0
Published:
DOI: https://doi.org/10.1186/s40364-024-00574-0